Evidence map›Paper›PMID 25017952›Full record

ArticleExpert review of vaccines2014

Will studies in individuals with systemic lupus erythematosus be the key to future HIV vaccine design?

Mattia Bonsignori

Open access · bronzeAbstract readEditorial
In one paragraph

Article in Expert review of vaccines, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Mattia BonsignoriDuke Human Vaccine Institute, Duke University Medical Center, MSRB II - Room 4013, PO Box 103020, 2 Genome Court, Durham, NC 27710, USA.
Duke University · US

Funding

Viral Sequencing CoreU19AI067854 · NIAID · DUKE UNIVERSITY · PI LETVIN, NORMAN L · 2006 to 2011
$290.5M
Virus biology scientific research support componentUM1AI100645 · NIAID · DUKE UNIVERSITY · PI MCMICHAEL, ANDREW JAMES · 2012 to 2018
$204.7M
Viral and Host Determinants of HIV-1 TransmissionU01AI067854 · NIAID · DUKE UNIVERSITY · PI HAYNES, BARTON F · 2005 to 2005
$14.9M
NIAID NIH HHS AI067854NIAID NIH HHS AI100645NIAID NIH HHS U01 AI067854NIAID NIH HHS U19 AI067854NIAID NIH HHS UM1 AI100645
6 · The paper itself

Abstract

The induction of HIV-1 broadly neutralizing antibodies (bnAbs) remains the primary goal of a preventive HIV-1 vaccine but no HIV-1 vaccine candidate has succeeded in inducing bnAbs. All the bnAbs isolated from chronically HIV-1 infected subjects display one or more traits associated with control by host tolerance and immunoregulatory mechanisms, including reactivity against self antigens. Recent studies on a HIV-1 patient with concurrent systemic lupus erythematosus have informed on how similar bnAbs are to typical autoantibodies controlled by immune tolerance mechanisms. Future studies aimed at elucidating the intersection between autoantibodies generated in the context of systemic lupus erythematosus and the development of HIV-1 bnAbs will further our knowledge of specific roadblocks that hamper the production of bnAbs and, ultimately, inform us on how to implement vaccine strategies to circumvent them.

Indexed as

AIDS VaccinesAntibodies, NeutralizingAutoantibodiesHIV-1HIV AntibodiesHIV InfectionsHumansImmune ToleranceLupus Erythematosus, SystemicAIDS VaccinesAntibodies, NeutralizingAutoantibodiesHIV Antibodiesautoreactive antibodyautoreactivityHIV-1 broadly neutralizing antibodiesHIV-1 vaccineHIV-1 vaccine designimmune toleranceSLEsystemic lupus erythematosus

Identifiers

PMID25017952
PMCPMC4331125
OpenAlexW1979597418

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.